SynthesisEndocrine2020

Do reductions in risk of cardiorenal events with SGLT2 inhibitors in type 2 diabetes vary with baseline characteristics? A meta-analysis.

Mei Qiu et al.PubMed ↗Publisher ↗

No numbers read from the abstract.